AZ’ Farxiga hits all goals in chronic kidney disease trial
The drug significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type II diabetes
Read More
Tag: DAPA-CKD
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
